NASDAQ:CALA Calithera Biosciences - CALA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.15 -0.22 (-58.92%) (As of 02/2/2023 10:03 AM ET) Add Compare Share Share Today's Range$0.11▼$0.3450-Day Range$0.37▼$3.6252-Week Range$0.11▼$13.38Volume14,424 shsAverage Volume673,010 shsMarket Capitalization$730,500.00P/E RatioN/ADividend YieldN/APrice Target$18.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Calithera Biosciences MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside9,186.9% Upside$18.67 Price TargetShort InterestBearish8.73% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.22Based on 3 Articles This WeekInsider TradingSelling Shares$47,320 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($8.62) to ($3.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 stars 3.2 Analyst's Opinion Consensus RatingCalithera Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.67, Calithera Biosciences has a forecasted upside of 9,186.9% from its current price of $0.20.Amount of Analyst CoverageCalithera Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.73% of the float of Calithera Biosciences has been sold short.Short Interest Ratio / Days to CoverCalithera Biosciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calithera Biosciences has recently increased by 34.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCalithera Biosciences does not currently pay a dividend.Dividend GrowthCalithera Biosciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCalithera Biosciences has received a 68.66% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Calithera Biosciences is -1.11. Previous Next 2.9 News and Social Media Coverage News SentimentCalithera Biosciences has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Calithera Biosciences this week, compared to 1 article on an average week.Search Interest8 people have searched for CALA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows5 people have added Calithera Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calithera Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,320.00 in company stock.Percentage Held by InsidersOnly 6.60% of the stock of Calithera Biosciences is held by insiders.Percentage Held by InstitutionsOnly 33.73% of the stock of Calithera Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Calithera Biosciences are expected to grow in the coming year, from ($8.62) to ($3.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Calithera Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Calithera Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalithera Biosciences has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Calithera Biosciences (NASDAQ:CALA) StockCalithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.Read More Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CALA Stock News HeadlinesFebruary 1, 2023 | americanbankingnews.comCalithera Biosciences, Inc. (NASDAQ:CALA) Director Deepika Pakianathan Sells 121,333 SharesJanuary 31, 2023 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Now Covered by Analysts at StockNews.comFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 24, 2023 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Earns Hold Rating from Analysts at StockNews.comJanuary 11, 2023 | marketwatch.comCalithera Biosciences Shares Plummet on Liquidation Plans >CALAJanuary 11, 2023 | marketwatch.comCalithera Biosciences to Liquidate >CALAJanuary 10, 2023 | finance.yahoo.comBiotech company Calithera plans its own death. Will others follow?January 9, 2023 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 9, 2023 | markets.businessinsider.comCalithera Biosciences Board Of Directors Determine Dissolution Of CompanyJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Stock Nosedives On Complete Liquidation, DissolutionJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionNovember 15, 2022 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 15, 2022 | seekingalpha.comCalithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comCalithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 8, 2022 | finance.yahoo.comCalithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022October 3, 2022 | marketwatch.comCalithera Biosciences Gets FDA Fast Track For Lung Cancer DrugOctober 3, 2022 | nasdaq.comCalithera Gets FDA Fast Track Designation For Sapanisertib For Squamous Lung Cancer TreatmentOctober 3, 2022 | finance.yahoo.comCalithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung CancerOctober 3, 2022 | finance.yahoo.comCalithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidateOctober 1, 2022 | seekingalpha.comCALA Calithera Biosciences, Inc.September 21, 2022 | reuters.comCalithera Biosciences IncSeptember 17, 2022 | finance.yahoo.com3 Penny Stocks With Surprisingly Superior FundamentalsSeptember 6, 2022 | finance.yahoo.comCalithera to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 16, 2022 | finance.yahoo.comCompanies Like Calithera Biosciences (NASDAQ:CALA) Could Be Quite RiskyAugust 16, 2022 | finance.yahoo.comCalithera Biosciences Reports Second Quarter 2022 Financial Results and Recent HighlightsAugust 16, 2022 | seekingalpha.comCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2022 Results - Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CALA Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CALA CUSIPN/A CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees92Year Founded2010Price Target and Rating Average Stock Price Forecast$18.67 High Stock Price Forecast$30.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+12,344.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($25.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-115,090,000.00 Net MarginsN/A Pretax Margin-1,530.22% Return on Equity-919.76% Return on Assets-103.32% Debt Debt-to-Equity RatioN/A Current Ratio3.76 Quick Ratio3.76 Sales & Book Value Annual Sales$9.75 million Price / Sales0.07 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book0.07Miscellaneous Outstanding Shares4,870,000Free Float4,544,000Market Cap$730,500.00 OptionableOptionable Beta1.06 Social Links Key ExecutivesSusan M. MolineauxPresident, Chief Executive Officer & DirectorStephanie WongCFO, Secretary & Chief Accounting OfficerSusan B DemoSenior Vice President-R&D OperationsFrancesco ParlatiSenior Vice President-ResearchEmil T. KuriakoseChief Medical OfficerKey CompetitorsInMed PharmaceuticalsNASDAQ:INMStatera BiopharmaNASDAQ:STABAltamira TherapeuticsNASDAQ:CYTOChina SXT PharmaceuticalsNASDAQ:SXTCPanbela TherapeuticsNASDAQ:PBLAView All CompetitorsInsiders & InstitutionsDeepika PakianathanSold 121,333 sharesTotal: $47,319.87 ($0.39/share)Primecap Management Co. CASold 5,800 shares on 11/15/2022Ownership: 8.520%Citadel Advisors LLCSold 11,794 shares on 11/15/2022Ownership: 4.100%Vanguard Group Inc.Bought 26,800 shares on 11/15/2022Ownership: 2.903%BlackRock Inc.Sold 9,367 shares on 11/15/2022Ownership: 1.725%View All Insider TransactionsView All Institutional Transactions CALA Stock - Frequently Asked Questions Should I buy or sell Calithera Biosciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALA, but not buy additional shares or sell existing shares. View CALA analyst ratings or view top-rated stocks. What is Calithera Biosciences' stock price forecast for 2023? 3 Wall Street research analysts have issued 12 month price objectives for Calithera Biosciences' shares. Their CALA share price forecasts range from $8.00 to $30.00. On average, they anticipate the company's stock price to reach $18.67 in the next year. This suggests a possible upside of 5,012.8% from the stock's current price. View analysts price targets for CALA or view top-rated stocks among Wall Street analysts. How have CALA shares performed in 2023? Calithera Biosciences' stock was trading at $3.26 at the start of the year. Since then, CALA stock has decreased by 88.8% and is now trading at $0.3651. View the best growth stocks for 2023 here. When is Calithera Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our CALA earnings forecast. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) released its earnings results on Monday, November, 14th. The biotechnology company reported ($2.01) earnings per share for the quarter, missing analysts' consensus estimates of ($1.99) by $0.02. When did Calithera Biosciences' stock split? Shares of Calithera Biosciences reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). What is Calithera Biosciences' stock symbol? Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA." Who are Calithera Biosciences' major shareholders? Calithera Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bvf Partners L P/Il, Deepika Pakianathan, Keith Orford, Stephanie Wong and Susan Molineaux. View institutional ownership trends. How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Calithera Biosciences' stock price today? One share of CALA stock can currently be purchased for approximately $0.37. How much money does Calithera Biosciences make? Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $1.78 million and generates $9.75 million in revenue each year. The biotechnology company earns $-115,090,000.00 in net income (profit) each year or ($25.60) on an earnings per share basis. How can I contact Calithera Biosciences? Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at ir@calithera.com. This page (NASDAQ:CALA) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.